相关临床试验
451
46 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
44
9.8%
已完成
358
79.4%
尚未招募
2
0.4%
招募中
30
6.7%
暂停
2
0.4%
终止
3
0.7%
撤回
12
2.7%
暂无批准数据
- An NCI-supported Children's Oncology Group phase 3 trial found adding blinatumomab to chemotherapy substantially improved disease-free survival in children newly diagnosed with B-cell acute lymphoblastic leukemia. - An NCI-led trial of about 50 patients supported FDA approval of atezolizumab for adults and children aged 2 and older with advanced alveolar soft part sarcoma. - NCI's Childhood Cancer Data Initiative provides no-cost tumor characterization at diagnosis, returning clinically relevant results to clinicians within 2-3 weeks. - NCI leaders emphasize sustained federal investment is needed because all childhood cancers are rare and commercial incentives to develop pediatric treatments remain limited.
- The Cancer Foundation of Santa Barbara awarded a $90,000 grant to Cottage Children's Medical Center to fund a Pediatric Research Coordinator supporting Children's Oncology Group clinical trials. - Cottage Children's Medical Center is the only Central Coast site where families can access COG pediatric cancer clinical trials, with four studies open and four patients on active protocol therapy in early 2026. - A $5,000 grant to Teddy Bear Cancer Foundation supported financial, emotional, and educational programs serving more than 135 families in the first half of 2026. - The overall 5-year survival rate for pediatric cancers rose from 63% in the mid-1970s to 87% in 2015–2021, driven by advances from clinical research and trial participation.
- The Children's Oncology Group AALL1731 trial received the David Sackett Trial of the Year Award for demonstrating that adding blinatumomab to chemotherapy reduces relapse risk by about two-thirds in children with B-cell acute lymphoblastic leukemia. - Children receiving the combination therapy achieved a 96% three-year disease-free survival rate compared to 87.9% with chemotherapy alone, representing a 61% reduction in risk of relapse, secondary malignancy, or remission-related death. - The study findings have established a new standard of care for pediatric B-ALL worldwide and represent the biggest breakthrough in childhood cancer treatment in decades. - The trial enrolled 4,264 newly diagnosed patients and ended early in July 2024 after interim analysis showed better outcomes than expected with the combination therapy.
- Black and Hispanic children with high-risk neuroblastoma experience significantly worse survival outcomes compared to white peers, even when treated in standardized clinical trials, according to new research from UT Southwestern Medical Center. - The study, published in JAMA Network Open, found Hispanic children had nearly 80% higher risk of death after induction treatment, while both Black and Hispanic children showed lower survival rates in post-consolidation trials. - Researchers found no significant racial or ethnic differences in care delivery or treatment delays, suggesting social determinants of health may play a crucial role in outcome disparities.
- A clinical trial demonstrated that adding blinatumomab to chemotherapy significantly improves three-year disease-free survival (DFS) rates in children with standard-risk acute lymphoblastic leukemia (ALL). - The trial reported a 96% three-year DFS rate for children receiving blinatumomab plus chemotherapy, compared to 87.9% with chemotherapy alone, marking a substantial improvement in outcomes. - Blinatumomab was well-tolerated, paving the way for reducing the use of more toxic chemotherapy drugs and improving the quality of life for young patients with B-cell ALL. - The Children's Oncology Group (COG) is incorporating blinatumomab into standard protocols, signaling a paradigm shift in the treatment of pediatric ALL and a new standard of care.
- Larotrectinib demonstrates high effectiveness in pediatric patients with newly diagnosed infantile fibrosarcoma (IFS) and other solid tumors harboring NTRK gene fusions. - The study marks the first Children's Oncology Group (COG) trial to assess precision medicine in a front-line setting based on genetic biomarkers. - Results indicate larotrectinib could replace chemotherapy as a first-line treatment for NTRK fusion-positive tumors, reducing potential harm to developing organs. - The objective response rate within six cycles was 94% for IFS and 60% for other solid tumors, highlighting the drug's potential in pediatric cancer care.
- The Children's Oncology Group has prioritized several novel agents for osteosarcoma treatment, addressing the lack of progress in outcomes for decades. - Multitargeted tyrosine kinase inhibitors are identified for frontline evaluation and will be incorporated into an upcoming phase III study. - Immunotherapies targeting B7-H3 and CD47-SIRPα inhibitors, telaglenastat, and epigenetic modifiers are also under consideration for clinical trials. - The New Agents for Osteosarcoma Task Force will continue to reassess and evaluate novel agents as new data become available.
- A phase 1 trial of lorlatinib in ALK-driven refractory neuroblastoma demonstrated safety and efficacy across all common ALK mutations, with a recommended pediatric dose of 115 mg/m² daily - approximately twice the adult dose. - Adolescents and adults with ALK-driven neuroblastoma showed particularly strong responses to lorlatinib, with a 47% objective response rate and 67% modified response rate including minor responses. - Serial circulating tumor DNA analysis revealed two key resistance mechanisms: compound ALK mutations (F1174L/G1202R, F1174L/L1196M) and mutations in the RAS-MAPK pathway, providing insights for future treatment strategies.
